A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Inclusion Criteria:

• Medically stable on the basis of physical examination, medical history, and vitalsigns, performed at screening. Any abnormalities must be consistent with theunderlying illness in the study population and this determination must be recordedin the participant's source documents and acknowledged by the investigator

• Must have had UC diagnosed prior to screening

• Have moderately to severely active UC, defined as a baseline Mayo score of 6 through 12, inclusive, with a screening Mayo endoscopy subscore greater than or equal to (>=) 2 as determined by a central review of the video of the endoscopy

• A participant who has had extensive colitis for >= 8 years, or disease limited tothe left side of the colon for >= 10 years, must: a) have had a full colonoscopy toassess for the presence of dysplasia within 1 year before the first administrationof study intervention or b) have a full colonoscopy with surveillance for dysplasiaas the baseline endoscopy during the screening period. Results from thesesurveillance biopsies must be negative for dysplasia (low-grade, high-grade, orindeterminant) prior to the first administration of study intervention

• Females of childbearing potential must have a negative highly sensitive urinepregnancy test at screening and at Week I-0 prior to study interventionadministration

Exclusion Criteria:

• Have UC limited to the rectum only or to less than (<) 20 centimeter (cm) of thecolon

• Presence or history of colonic or small bowel obstruction within 6 months prior toscreening, confirmed by objective radiographic or endoscopic evidence of a stricturewith resulting obstruction (dilation of the colon or small bowel proximal to thestricture on barium radiograph or an inability to traverse the stricture atendoscopy)

• Have a history of latent or active granulomatous infection, histoplasmosis, orcoccidioidomycosis, or have had a nontuberculous mycobacterial infection prior toscreening

• Presence or history of any malignancy including presence or history oflymphoproliferative disease including lymphoma, or signs and symptoms suggestive ofpossible lymphoproliferative disease, such as lymphadenopathy of unusual size orlocation (example, nodes in the posterior triangle of the neck, infraclavicular,epitrochlear, or periaortic areas) and monoclonal gammopathy of undeterminedsignificance, or clinically significant hepatomegaly or splenomegaly

• Has known allergies, hypersensitivity, or intolerance to ustekinumab or itsexcipients